췌장암 정밀의료 시장 규모, 점유율, 동향 분석 보고서 : 치료 접근법별, 진단 기술별, 지역별, 부문 동향(2025-2030년)

Pancreatic Cancer Precision Medicine Market Size, Share & Trends Analysis Report By Therapeutic Approach (Targeted Therapy, Immunotherapy, Chemotherapy-precision Combinations), By Diagnostic Technology, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,242,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,627,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,398,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

췌장암 정밀의료 시장의 성장 및 동향

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 췌장암 정밀의료 시장 규모는 2030년까지 18억 8,000만 달러에 달할 것으로 예측되고, 예측 기간 동안 CAGR 19.2%로 성장할 것으로 전망됩니다. 췌장암 정밀 의학 산업은 생존율을 높이고 부작용을 최소화하는 표적 치료법과 면역 요법의 채택이 증가함에 따라 성장을 경험하고 있습니다. 액체 생검과 분자 프로파일링을 포함한 첨단 진단 도구는 조기 발견과 치료 효과를 개선했습니다. 이러한 정밀 의학으로의 전환은 보다 효과적이고 개별화된 치료 전략을 가능하게 했습니다.

특히 차세대 시퀀싱과 생물정보학의 통합과 같은 기술 발전은 새로운 치료 표적의 발견을 촉진하여 보다 효과적인 약물 설계를 가능하게 했습니다. 제약 회사, 학술 기관, 정부 기관은 투자를 늘려 혁신적인 치료법 개발을 지원했습니다. PanCAN 보조금 프로그램과 같은 이니셔티브는 췌장암 연구에 자금을 지원하여 시장 성장을 이끌었습니다.

생활 습관 요인과 인구 고령화의 영향으로 췌장암 발병률이 증가하면서 전문 치료법에 대한 수요가 높아졌습니다. 2024년 호주암협회는 호주에서 4,641건의 새로운 췌장암이 진단될 것으로 예상했습니다. 이러한 유병률 증가는 의료 서비스 제공자들이 보다 효과적인 옵션을 모색하면서 시장 성장을 촉진했습니다. 또한 제약회사와 연구 기관 간의 전략적 협업과 규제 지원은 시장 성장을 더욱 가속화했습니다.

췌장암 정밀의료 시장 보고서 하이라이트

• 치료 접근법별로, 표적 치료법이 시장을 지배했으며, 개인 맞춤형 치료 및 유전체 프로파일링의 발전으로 인해 2024년 56.0%의 점유율을 차지했습니다.
• 한편, 화학 요법-정밀 조합은 예측 기간 동안 가장 빠른 연평균 성장률(CAGR)로 성장할 것으로 예상됩니다.
• 진단 기술별로는 유전체 검사가 시장을 주도하며 2024년 40.8%를 차지할 것으로 예상됩니다. 실행 가능한 돌연변이를 식별하는 데 있어 유전체 검사의 역할은 개인 맞춤형 치료에 필수적인 것으로 입증되었습니다.
• 액체 생검은 ctDNA 및 CTC 분석을 통한 조기 발견을 위한 최소 침습적 방법으로, 환자 결과 개선에 힘입어 예측 기간 동안 20.3%의 가장 빠른 연평균 성장률(CAGR)을 기록할 것으로 예상됩니다.
• 첨단 진단과 함께 표적 치료 및 면역 요법의 채택이 증가함에 따라 생존율을 높이고 효과적인 정밀 의학 전략을 맞춤화함으로써 시장 성장을 촉진하고 있습니다.
• 북미는 높은 발병률과 효과적인 치료법에 대한 수요로 인해 42.9%의 매출 점유율로 전 세계 췌장암 정밀 의학 산업을 주도하고 있습니다.
• 췌장암 정밀의료 산업에서 사업을 전개하는 시장 진출기업은 AstraZeneca, Pfizer Inc., Novartis AG, Amgen Inc., F. Hoffmann-La Roche Ltd, Bayer AG, Eli Lilly and Company, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd, llumina, Inc., Thermo Fisher Scientific Inc., FOUNDATION MEDICINE, INC를 포함합니다.
• 2024년 8월 Illumina Inc.는 NovaSeq X 시리즈 고객을 위한 새로운 종양학 메뉴를 출시하여 전 세계 고객에게 더 낮은 비용과 더 큰 규모로 포괄적인 유전체 프로파일링을 확대했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 췌장암 정밀의료 시장의 변수, 동향, 범위

• 시장 계통의 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 비즈니스 환경 분석
  • 산업 분석 - Porter's Five Forces 분석
  • PESTLE 분석

제4장 췌장암 정밀의료 시장 : 치료 접근법별 사업 분석

• 치료 접근법별 시장 점유율(2024년, 2030년)
• 치료 접근법별 부문 대시보드
• 시장 규모와 예측과 동향 분석, 치료 접근법별(2018-2030년)
• 표적요법
• PARP 억제제
• 단일클론항체
• 저분자 억제제-EGFR 억제제, KRAS 억제제
• 면역 요법
• 면역관문억제제-PD-1 억제제, PD-L1 억제제
• 암 백신-GVAX, 아르겐판투셀-L
• 입양 T 세포 요법-CAR-T 요법
• 화학 요법-정밀 조합
• 기타

제5장 췌장암 정밀의료 시장 : 진단 기술별 비즈니스 분석

• 진단 기술별 시장 점유율(2024년, 2030년)
• 진단 기술별 부문 대시보드
• 시장 규모와 예측과 동향 분석, 진단 기술별(2018-2030년)
• 유전체 검사
• 분자 진단
• 액체 생검
• 바이오마커 기반 동반진단
• 기타(면역조직화학(IHC), 단백질체학, 질량분석)

제6장 췌장암 정밀의료 시장 : 지역별, 추정 및 동향 분석

• 지역별 시장 점유율 분석(2024년, 2030년)
• 지역별 시장 대시보드
• 시장 규모와 예측 동향 분석(2018-2030년)
• 북미
  • 국가별(2018-2030년)
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 국가별(2018-2030년)
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 덴마크
  • 스웨덴
• 아시아태평양
  • 국가별(2018-2030년)
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 국가별(2018-2030년)
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 국가별(2018-2030년)
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제7장 경쟁 구도

• 참가자 개요
• 기업의 시장 포지셔닝 분석
• 기업 분류
• 전략 매핑
• 기업 프로파일 및 상장 기업
  • AstraZeneca
  • Pfizer Inc.
  • Novartis AG
  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd
  • Bayer AG
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd
  • PharmaCyte BIoTech, Inc.
  • Genentech, Inc.
  • Guardant Health
  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • FOUNDATION MEDICINE, INC.

HBR

영문 목차

영문목차

Pancreatic Cancer Precision Medicine Market Growth & Trends:

The global pancreatic cancer precision medicine market size is anticipated to reach USD 1.88 billion by 2030, registering a CAGR of 19.2% during the forecast period, according to a new report by Grand View Research, Inc. The pancreatic cancer precision medicine industry experiences growth due to the increasing adoption of targeted therapies and immunotherapies, which enhanced survival rates and minimized side effects. Advanced diagnostic tools, including liquid biopsies and molecular profiling, improved early detection and treatment efficacy. This shift towards precision medicine facilitated more effective, individualized treatment strategies.

Technological progress, specifically the integration of next-generation sequencing and bioinformatics, facilitated the discovery of new therapeutic targets, enabling more effective drug design. Pharmaceutical companies, academic institutions, and government organizations increased their investments, supporting the development of innovative therapies. Initiatives such as the PanCAN grants program demonstrated a commitment to funding pancreatic cancer research, driving market growth.

The rising incidence of pancreatic cancer, influenced by lifestyle factors and an aging population, created a higher demand for specialized treatments. In 2024, Cancer Australia estimated 4,641 new pancreatic cancer cases were diagnosed in the country. This growing prevalence propelled market growth as healthcare providers sought more effective options. Furthermore, strategic collaborations between pharmaceutical companies and research institutions and regulatory support further accelerated market growth.

Pancreatic Cancer Precision Medicine Market Report Highlights:

• Based on therapeutic approach, targeted therapy dominated the market and accounted for a share of 56.0% in 2024, owing to by advancements in personalized treatment and genomic profiling.
• Chemotherapy-precision combinations, on the other hand, is expected to grow at the fastest CAGR of over the forecast period.
• Based on diagnostic technology, genomic testing led the market and accounted for 40.8% in 2024. Its role in identifying actionable mutations proved essential for personalized treatment.
• Liquid biopsies, a minimally invasive method for early detection via ctDNA and CTC analysis, are projected to grow at the fastest CAGR of 20.3% over the forecast period, driven by improved patient outcomes.
• The increasing adoption of targeted therapies and immunotherapies, coupled with advanced diagnostics, fuels market growth by enhancing survival rates and tailoring effective precision medicine strategies.
• North America dominated the global pancreatic cancer precision medicine industry with a 42.9% revenue share, driven by high incidence rates and demand for effective treatments.
• Market players operating in the pancreatic cancer precision medicine industry include AstraZeneca; Pfizer Inc.; Novartis AG; Amgen Inc.; F. Hoffmann-La Roche Ltd; Bayer AG; Eli Lilly and Company; Merck & Co., Inc.; Teva Pharmaceutical Industries Ltd; PharmaCyte Biotech, Inc.; Genentech, Inc.; Guardant Health; Illumina, Inc.; Thermo Fisher Scientific Inc.; FOUNDATION MEDICINE, INC.
• In August 2024, Illumina Inc. launched a new oncology menu for its NovaSeq X Series customers, expanding comprehensive genomic profiling at lower costs and greater scale for customers worldwide.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Therapeutic Approach
  • 1.2.2. Diagnostic Technology
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Pancreatic Cancer Precision Medicine Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Pancreatic Cancer Precision Medicine Market: Therapeutic Approach Business Analysis

• 4.1. Therapeutic Approach Market Share, 2024 & 2030
• 4.2. Therapeutic Approach Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Therapeutic Approach, 2018 to 2030 (USD Million)
• 4.4. Targeted Therapy
  • 4.4.1. Targeted Therapy Market, 2018 - 2030 (USD Million)
• 4.5. PARP Inhibitors
  • 4.5.1. PARP Inhibitors Market, 2018 - 2030 (USD Million)
• 4.6. Monoclonal Antibodies
  • 4.6.1. Monoclonal Antibodies Market, 2018 - 2030 (USD Million)
• 4.7. Small Molecule Inhibitors - EGFR Inhibitors, KRAS Inhibitors
  • 4.7.1. Small Molecule Inhibitors - EGFR Inhibitors, KRAS Inhibitors Market, 2018 - 2030 (USD Million)
• 4.8. Immunotherapy
  • 4.8.1. Immunotherapy Market, 2018 - 2030 (USD Million)
• 4.9. Immune Checkpoint Inhibitors - PD-1 Inhibitors, PD-L1 Inhibitors
  • 4.9.1. Immune Checkpoint Inhibitors - PD-1 Inhibitors, PD-L1 Inhibitors Market, 2018 - 2030 (USD Million)
• 4.10. Cancer Vaccines - GVAX, Algenpantucel-L
  • 4.10.1. Cancer Vaccines - GVAX, Algenpantucel-L Market, 2018 - 2030 (USD Million)
• 4.11. Adoptive T-Cell Therapies - CAR-T Therapies
  • 4.11.1. Adoptive T-Cell Therapies - CAR-T Therapies Market, 2018 - 2030 (USD Million)
• 4.12. Chemotherapy-Precision Combinations
  • 4.12.1. Chemotherapy-Precision Combinations Market, 2018 - 2030 (USD Million)
• 4.13. Other Therapeutic Approaches
  • 4.13.1. Other Therapeutic Approaches Market, 2018 - 2030 (USD Million)

Chapter 5. Pancreatic Cancer Precision Medicine Market: Diagnostic Technology Business Analysis

• 5.1. Diagnostic Technology Market Share, 2024 & 2030
• 5.2. Diagnostic Technology Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Diagnostic Technology, 2018 to 2030 (USD Million)
• 5.4. Genomic Testing
  • 5.4.1. Genomic Testing Market, 2018 - 2030 (USD Million)
• 5.5. Molecular Diagnostics
  • 5.5.1. Molecular Diagnostics Market, 2018 - 2030 (USD Million)
• 5.6. Liquid Biopsy
  • 5.6.1. Liquid Biopsy Market, 2018 - 2030 (USD Million)
• 5.7. Biomarker-based Companion Diagnostics
  • 5.7.1. Biomarker-based Companion Diagnostics Market, 2018 - 2030 (USD Million)
• 5.8. Others (Immunohistochemistry (IHC), Proteomics, Mass Spectrometry)
  • 5.8.1. Others (Immunohistochemistry (IHC), Proteomics, Mass Spectrometry) Market, 2018 - 2030 (USD Million)

Chapter 6. Pancreatic Cancer Precision Medicine Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 6.4. North America
  • 6.4.1. North America Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Regulatory Framework
    • 6.4.2.3. Competitive Insights
    • 6.4.2.4. U.S. Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.4.3. Canada
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Regulatory Framework
    • 6.4.3.3. Competitive Insights
    • 6.4.3.4. Canada Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.4.4. Mexico
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Regulatory Framework
    • 6.4.4.3. Competitive Insights
    • 6.4.4.4. Mexico Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.5. Europe
  • 6.5.1. Europe Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.5.2. UK
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Regulatory Framework
    • 6.5.2.3. Competitive Insights
    • 6.5.2.4. UK Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.3. Germany
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Regulatory Framework
    • 6.5.3.3. Competitive Insights
    • 6.5.3.4. Germany Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.4. France
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Regulatory Framework
    • 6.5.4.3. Competitive Insights
    • 6.5.4.4. France Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.5. Italy
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Regulatory Framework
    • 6.5.5.3. Competitive Insights
    • 6.5.5.4. Italy Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.6. Spain
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Regulatory Framework
    • 6.5.6.3. Competitive Insights
    • 6.5.6.4. Spain Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.7. Norway
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Regulatory Framework
    • 6.5.7.3. Competitive Insights
    • 6.5.7.4. Norway Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.8. Denmark
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Regulatory Framework
    • 6.5.8.3. Competitive Insights
    • 6.5.8.4. Denmark Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.9. Sweden
    • 6.5.9.1. Key Country Dynamics
    • 6.5.9.2. Regulatory Framework
    • 6.5.9.3. Competitive Insights
    • 6.5.9.4. Sweden Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Regulatory Framework
    • 6.6.2.3. Competitive Insights
    • 6.6.2.4. Japan Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. China
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Regulatory Framework
    • 6.6.3.3. Competitive Insights
    • 6.6.3.4. China Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Regulatory Framework
    • 6.6.4.3. Competitive Insights
    • 6.6.4.4. India Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.5. South Korea
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Regulatory Framework
    • 6.6.5.3. Competitive Insights
    • 6.6.5.4. South Korea Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.6. Australia
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Regulatory Framework
    • 6.6.6.3. Competitive Insights
    • 6.6.6.4. Australia Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.7. Thailand
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Regulatory Framework
    • 6.6.7.3. Competitive Insights
    • 6.6.7.4. Thailand Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Regulatory Framework
    • 6.7.2.3. Competitive Insights
    • 6.7.2.4. Brazil Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Regulatory Framework
    • 6.7.3.3. Competitive Insights
    • 6.7.3.4. Argentina Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.8. MEA
  • 6.8.1. MEA Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Regulatory Framework
    • 6.8.2.3. Competitive Insights
    • 6.8.2.4. South Africa Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Regulatory Framework
    • 6.8.3.3. Competitive Insights
    • 6.8.3.4. Saudi Arabia Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Regulatory Framework
    • 6.8.4.3. Competitive Insights
    • 6.8.4.4. UAE Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Regulatory Framework
    • 6.8.5.3. Competitive Insights
    • 6.8.5.4. Kuwait Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. AstraZeneca
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. Pfizer Inc.
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. Novartis AG
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. Amgen Inc.
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. F. Hoffmann-La Roche Ltd
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. Bayer AG
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. Eli Lilly and Company
    • 7.5.7.1. Overview
    • 7.5.7.2. Financial Performance
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. Merck & Co., Inc.
    • 7.5.8.1. Overview
    • 7.5.8.2. Financial Performance
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. Teva Pharmaceutical Industries Ltd
    • 7.5.9.1. Overview
    • 7.5.9.2. Financial Performance
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic Initiatives
  • 7.5.10. PharmaCyte Biotech, Inc.
    • 7.5.10.1. Overview
    • 7.5.10.2. Financial Performance
    • 7.5.10.3. Product Benchmarking
    • 7.5.10.4. Strategic Initiatives
  • 7.5.11. Genentech, Inc.
    • 7.5.11.1. Overview
    • 7.5.11.2. Financial Performance
    • 7.5.11.3. Product Benchmarking
    • 7.5.11.4. Strategic Initiatives
  • 7.5.12. Guardant Health
    • 7.5.12.1. Overview
    • 7.5.12.2. Financial Performance
    • 7.5.12.3. Product Benchmarking
    • 7.5.12.4. Strategic Initiatives
  • 7.5.13. Illumina, Inc.
    • 7.5.13.1. Overview
    • 7.5.13.2. Financial Performance
    • 7.5.13.3. Product Benchmarking
    • 7.5.13.4. Strategic Initiatives
  • 7.5.14. Thermo Fisher Scientific Inc.
    • 7.5.14.1. Overview
    • 7.5.14.2. Financial Performance
    • 7.5.14.3. Product Benchmarking
    • 7.5.14.4. Strategic Initiatives
  • 7.5.15. FOUNDATION MEDICINE, INC.
    • 7.5.15.1. Overview
    • 7.5.15.2. Financial Performance
    • 7.5.15.3. Product Benchmarking
    • 7.5.15.4. Strategic Initiatives

관련자료